Ocampo-Garza SS, Vastarella M, Donnarumma M, Nappa P, Cantelli M, Villani A, Fabbrocini G, Ocampo-Candiani J

Language: English
References: 9
Page: 263-264
PDF size: 101.54 Kb.

ABSTRACT

Recent studies suggest men are more affected by coronavirus disease than women. Coronavirus infectivity depends on the entry via; it binds its viral spike (S) protein to the angiotensinconverting enzyme 2 (ACE2) receptor, and on S protein priming by transmembrane serine protease type ll (TMPRSS2). The androgen receptor activity is required for the TMPRSS2 transcription. ACE2 is also affected by androgenic hormones. This androgen-dependent regulation in the lungs may explain the increased susceptibility of men to COVID-19 infection. Androgen deprivation therapies may represent a promising treatment against SARS-COV-2 infection.

REFERENCES

1. Montopoli M, Zumerle S, Vettor R et al., Androgen-deprivation therapiesfor prostate cancer and risk of infection by sars-cov-2: a population-based study (n = 4 532), Ann Oncol 2020; 31:1040-45.

2. Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguere T. covid-19 andthe male susceptibility: the role of ace2, tmprss2 and the androgenreceptor, Prog en Urol 2020; 30:484-7.

3. Cadegiani FA, Goren A y Wambier CG, Spironolactone may provideprotection from sars-cov-2: targeting androgens, angiotensin convertingenzyme 2, and renin-angiotensin-aldosterone system, MedHypotheses 2020; 143:110112.

4. Wambier CG, Goren A, Vaño-Galván S et al., Androgen sensitivity gatewayto covid-19 disease severity, Drug Dev Res 2020; 81:771-6.

5. Wambier CG, Vaño-Galván S, McCoy J et al., Androgenetic alopeciapresent in the majority of patients hospitalized with covid-19: the“Gabrin sign”, J Am Acad Dermatol 2020; 83:680-82.

6. Patel VG, Zhong X, Liaw B et al., Does androgen deprivation therapyprotect against severe complications from covid-19?, Ann Oncol 2020;31:1419-20.

7. McCoy J, Id O, Wambier C et al., 5-Alpha-reductase inhibitors are associatedwith reduced frequency of covid-19 symptoms in males withandrogenetic alopecia, J Eur Acad Dermatol Venereol 2021; 35:e243-6.

8. Goren A, Wambier CG, Herrera S et al., Anti-androgens may protectagainst severe covid-19 outcomes: results from a prospective cohortstudy of 77 hospitalized men, J Eur Acad Dermatol Venereol 2021; 35:e13-5.

9. Cadegiani F, McCoy J, Wambier CG et al., Proxalutamide significantlyaccelerates viral clearance and reduces time to clinical remission inpatients with mild to moderate covid-19: results from a randomized,double-blinded, placebo-controlled trial, Cureus 2021; 13(2):e13492.